Christina Brzezniak, DO
Hematology & Oncology · Reston, VANPI 1356590004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,062 and has fallen 50.2% since, to $528 in 2025.
Across 108 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$458
- Novartis$406
- Daiichi Sankyo Inc.$364
- Merck$237
- Pfizer$211
- Genentech USA, Inc.$204
- plus $959 from 28 others
Across 293 payments — averaging $2817.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$492K
- Gilead$203K
- Pfizer$79K
- Janssen Research & Development, LLC$22K
- AstraZeneca$14K
- Genentech, Inc.$9K
- plus $8K from 1 others
What the payments were for
- Food & beverage$2,71796%
- Education$1224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 12 | $458 |
| Novartis | 15 | $406 |
| Daiichi Sankyo Inc. | 11 | $364 |
| Merck | 11 | $237 |
| Pfizer | 9 | $211 |
| Genentech USA, Inc. | 8 | $204 |
| Eisai Inc. | 4 | $96 |
| AbbVie | 2 | $63 |
| GSK | 3 | $62 |
| AstraZeneca | 2 | $61 |
| Puma Biotechnology, Inc. | 3 | $58 |
| Incyte Corporation | 2 | $47 |
| Rigel Pharmaceuticals, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $43 |
| Astellas Pharma US Inc | 2 | $40 |
| Acrotech Biopharma Inc. | 2 | $36 |
| Myriad Genetic Laboratories, Inc. | 1 | $34 |
| Seagen Inc. | 1 | $33 |
| EMD Serono, Inc. | 1 | $29 |
| Gilead | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Amgen | 1 | $27 |
| Sanofi | 1 | $26 |
| Coherus Oncology, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Novocure Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Medtronic | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Array Biopharma Inc | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$125
How this compares
$2,839 in reported general payments places this provider in the 60th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 15 | $245,964 |
| IbrancePalbociclib | 13 | $209,453 |
| TafinlarDabrafenib Mesylate | 12 | $154,599 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $134,787 |
| EliquisApixaban | 56 | $42,487 |
| XareltoRivaroxaban | 16 | $22,166 |
| Enoxaparin Sodium | 19 | $5,331 |
| Letrozole | 62 | $1,965 |
| Anagrelide Hcl | 13 | $1,151 |
| Hydroxyurea | 45 | $760 |
| Tamoxifen Citrate | 32 | $745 |
| Anastrozole | 40 | $601 |
| Dexamethasone | 33 | $315 |
| Prochlorperazine Maleate | 16 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTafinlar, Mekinist | $406 | $289,38623 claims |
| PfizerIbrance, Eliquis | $211 | $251,94069 claims |
| AstraZenecaTagrisso | $61 | $245,96415 claims |
| Johnson & JohnsonXarelto | $458 | $22,16616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Reston
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.